US$ 20.39
glp 1 drug novo nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article Novo Nordisk promotes new GLP-1
Description
IntroductionWith the rise in glucagon-like peptide 1 receptor agonist (GLP-1RA) medication usage for Type 2 diabetes mellitus and weight loss, concerns have ...

No commitment: Month-to-month billing

A group of medications called GLP-1 agonists, originally used for diabetes, may help protect kidneys and improve heart health

Time-to-onset analysis revealed a median latency of 32 days (IQR 7122) for GLP-1 RA-related NAEs, with 45.28% occurring within 30 days of treatment initiation
